J&J quietly punts a pair of early-stage bispecifics for solid tumors
Johnson & Johnson has put two early-stage bispecific antibodies on the backburner, the pharma giant revealed as part of its quarterly update.
Listed in the …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
